08:00 EDT Maze Therapeutics (MAZE) up 15% at $56.43 after Q4 results and MZE829 trial data
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
- Maze Therapeutics adds Neil Kumar to board leadership
- Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
- Maze Therapeutics initiated with a Buy at Truist
- Maze Therapeutics price target raised to $58 from $43 at Wedbush